AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
1min snip
The Scientific Journey Behind Ozempic (with Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor)
ACQ2 by Acquired
Slow Progress with Consistent Positive Data
The slow progress of GOP one based medicines may have contributed to their success as decades of positive data continued to emerge. Research suggests that once about 15% of the population is aware of something, it can significantly gain momentum. Despite disappointments in the obesity pharma area, the consistent release of positive data over time may have played a significant role in the ultimate success of GOP one medications.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode